WO2020112038A1 - Procédé d'obtention d'un nanoparticulaire à additif d'argile - Google Patents

Procédé d'obtention d'un nanoparticulaire à additif d'argile Download PDF

Info

Publication number
WO2020112038A1
WO2020112038A1 PCT/TR2018/050743 TR2018050743W WO2020112038A1 WO 2020112038 A1 WO2020112038 A1 WO 2020112038A1 TR 2018050743 W TR2018050743 W TR 2018050743W WO 2020112038 A1 WO2020112038 A1 WO 2020112038A1
Authority
WO
WIPO (PCT)
Prior art keywords
nano
delivery component
drug
obtaining
particulates according
Prior art date
Application number
PCT/TR2018/050743
Other languages
English (en)
Inventor
Mehmet Sabri ÇELİK
Adem TEKİN
Deniz KARATAŞ
Fatemeh BAHADORİ
Original Assignee
Bezmi̇alem Vakif Üni̇versi̇tesi̇
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bezmi̇alem Vakif Üni̇versi̇tesi̇ filed Critical Bezmi̇alem Vakif Üni̇versi̇tesi̇
Priority to KR1020217007844A priority Critical patent/KR20210090606A/ko
Priority to PCT/TR2018/050743 priority patent/WO2020112038A1/fr
Publication of WO2020112038A1 publication Critical patent/WO2020112038A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5115—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)

Definitions

  • the invention relates to clay additive nano-particulate obtaining method.
  • the invention particularly relates to a method for obtaining nano-particulates formed by means of making polylactide-co-glicolide (PLGA) mycelium stable by use of very low rates of sodium-montmorillonite (Na-MMT) in order to obtain a drug carrying system of self-assembly for use in intravenous (iv) applications for cancer treatment.
  • PLGA polylactide-co-glicolide
  • Na-MMT sodium-montmorillonite
  • Some disadvantages may occur during application of chemotherapy. Effective agents can be distributed to entire body through blood circulation and toxic effect may occur. Cancer medicine cannot progress into tumour area in adequate amount and its effect may decrease. In order to eliminate such disadvantages, obtaining effective results by use of lower dosage of medicine, administration of medicine to patient with bio-compatible composites and shortening treatment period can be provided by various treatment methods. Said treatment methods are drug delivery systems defined as“targeted cancer treatment”. Drug delivery systems can be administered orally as well as intravenously (iv) as preferred in cancer treatments in particular. Today among targeted cancer treatments, passive targeting and nano-biotechnological methods are the ones showing the most development.
  • Passive targeting method is provided by means of concentrating the drug on a point requiring effect of the used drug due to natural features and physiological structure of the tissue. Endothelial cells forming the blood vessels in tumour area are in more separated (about 200 nm) in comparison to those of healthy tissues.
  • drug delivery system is provided to penetrate into tumour area in passive way when passing through such areas. This effect is defined as the enhanced permeability and retention (EPR) effect.
  • EPR enhanced permeability and retention
  • the drug delivery system has to deliver the drug molecules to the target area without leakage and nano particulate sizes must be under 200 nm.
  • targeted drug delivery systems in use today have problems in meeting these two requirements. For instance, drug molecules may leak from walls of liposome formulations or may form in various undesired sizes during formation.
  • Nano-biotechnological methods are used in self-assembled (SA) drug delivery systems.
  • SA self-assembled
  • Such systems are formed by means of combining amphiphilic materials consisting of hydrophilic or hydrophobe blocks in aqua ambience by exposing hydrophilic parts to water and avoiding hydrophobic parts from water. Delivery of drug molecules or interaction with such structure forming subject to feature of drug molecule to resolve in water, with hydrophilic or hydrophobic parts provides delivery.
  • the constituted structures are generally in spherical form subject to concentration of amphiphilic material. When spherical forms are defined as supramolecular structure and the chains forming such structure as monomer, the structure of monomers provides formation of single or double layer supramolecular structures.
  • Monomers in square or rectangular morphology constitute liposomes while triangle form monomers constitute mycelium.
  • Formation of SA drug delivery systems obtained in any circumstances is subject to hydrophobic-hydrophobic attraction forces. And this case causes easy distribution particularly in capillaries having high pressure and areas near cardiac pump without delivery of drug to tumour areas by the nano-particulates.
  • this disadvantageous case does not prevent use of said systems.
  • causes for such cases are high drug delivery capacity, having sizes under 200 nm, simple production technologies arising from easy formation in water and most importantly, existence of multiple bio-compatible and bio-degradable amphiphilic materials.
  • Use of SA drug delivery systems in targeted cancer treatment is considerably common because of said causes on which various studies have been conducted to provide its development.
  • Bio-compatible PLGA is an amphiphilic material used in formation of SA drug delivery systems and used for delivery of many biological active agents from small drug molecules to peptide and proteins. Behaviour of this amphiphilic polymer is controlled by factors such as stereo-chemistry of lactic acid, crystal degree, lactic acid/glycolic acid rate and molecular weight etc. This amphiphilic material exposes the blocks insoluble in water to water and collects the parts disliking water, in the nucleic part and forms supramolecular aggregate similar to mycelium.
  • US20060193787A1 discloses development of an orally taken drug delivery system by use of MMT.
  • nanoparticle anticancer paclitaxel molecules prepared by use of PLGA and MMT were given and oral formulation use is suggested.
  • Polyvinyl alcohol (PVA) polymer was used for exfoliation of clay and the size of particulate obtained as a result was 305 nm.
  • the size of clay in this delivery composite is too high for intravenous applications.
  • aggregate formation occurs in nanoparticles when centrifuge is used to remove PVA residue in production stage.
  • the application numbered TR 2017/1 1955 discloses a method of obtaining a bioactive component eluting nanocomposite and basically relates to an orally taken drug delivery system.
  • the application discloses a method for obtaining a bioactive component eluting nanocomposite obtained by use of at least a bioactive component showing bioavailability without use of any organic solvent, a nano delivery agent of layer structure and obtained from an agent of delivery feature by centrifuging and homogenisation method and by use of an additive enhancing interaction of bioactive component with nano agent.
  • the most important part of the application of the bioactive component eluting nanocomposite is that it is applied after dissolution in a fluid.
  • This present invention relates to a method for obtaining a clay additive nano-particulate for cancer treatment in order to eliminate above mentioned disadvantages and provide new advantages in the related art.
  • Main purpose of the invention is to disclose a method for obtaining a nano-particulate which can be administered intravenously (iv) for targeted cancer treatment.
  • Another purpose of the invention is to disclose a method for obtaining a nanoparticulate wherein dialysis membrane technique is used without need for use of any extra chemicals.
  • a further purpose of the invention is to disclose a method for obtaining a nano-particulate not containing any surfactant or any other similar toxic agents.
  • Another purpose of the invention is to disclose a method for obtaining a characteristic and smoothly dispersed nanoparticulate in sizes under 200 nm.
  • a further purpose of the invention is to disclose a method for obtaining nanoparticulate from a nano agent wherein layered structure of natural clay minerals is used as joining clips.
  • Another purpose of the invention is to disclose a method for obtaining nanoparticulate wherein nano agent size is under 100 nm.
  • Another purpose of the invention is to disclose a method for obtaining a nanoparticulate allowing placement of any drug molecules therein.
  • the present inventions relate to a method for obtaining nano-particulates used in drug delivery system comprising procedure steps of: a) reducing a delivery component into nano-delivery component by grinding in an attritor,
  • nanoparticulates comprising a nano-delivery component in range of 17.5 - 73 % and preferably 28.08 % by weight.
  • nanoparticulates comprising an additive polymer in range of 27 - 79,5 % and preferably 70,22 % by weight.
  • nanoparticulates comprising a drug in range of 0 - 3 % and preferably 1 ,7 % by weight.
  • a further characteristic of the method disclosed under the invention is that said nano delivery component is average 30 nm in size.
  • Another characteristic of the method disclosed under the invention is that the process of keeping nano-delivery component in water in said step (b) lasts at least for 2 hours.
  • a further characteristic of the method disclosed under the invention is that obtained aqueous nano delivery component is preferably 20 ml and 0,1 % w/v.
  • Another characteristic of the method disclosed under the invention is that the solution comprising the additive polymer and the drug in said step (c) is preferably 5 ml.
  • a further characteristic of the method disclosed under the invention is that the dialysis membrane operation in said step (d) is conducted at preferably 37 °C and for at least 24 hours.
  • a further characteristic of the method disclosed under the invention is that said nano particulate size is preferably 120 nm.
  • said nano delivery component is a clay mineral having layered structure and is preferably natural Na-MMT from Tokat Re ⁇ adiye region in Turkey.
  • a further characteristic of the method disclosed under the invention is that said additive polymer is preferably PLGA.
  • a further characteristic of the method disclosed under the invention is that the obtained nanoparticulates in SA drug delivery system can be administered intravenously.
  • the invention is basically a nanoparticulate composed of a layered nano delivery, an additive polymer and a drug.
  • Method for obtaining said nanoparticulate is achieved in preferably 3 stages.
  • delivery component is reduced to nano size by use of mechanical-physical nanoparticle production processes.
  • an additive polymer dissolved in acetone, and a drug are added to the solvent consisting of delivery agent reduced to nano size.
  • dialysis membrane technique the obtained mixture is transformed into nanoparticulates which are appropriate for use in drug delivery system and can be administered intravenously.
  • the delivery component is reduced into under micrometer size in wet medium by use of attritor device of preferably model“Union Process 01 -HD”.
  • This device also performs cutting and milling operations in addition to dispersion and grinding processes.
  • For conduct of the procedure firstly device is operated at low revolutions per minute (150-450 rpm). After grinder and liquid pulp are thoroughly mixed, chamber of the device is fed with delivery component sample in rate of 1 ⁇ 4. Then the device is operated at 2400 rpm.
  • the procedure is performed at preferably room temperature. Cooling or heating may cause failure of delivery component so the cooling water was constantly run in process.
  • Nano delivery components of average 30 nm in size are obtained.
  • Nano delivery component is waited in water for preferably at least 2 hours. This procedure is required for maximum interaction between the drug to be obtained in the next step and additive polymer mixer.
  • additive polymer and drug are dissolved in acetone at room temperature during the next stage too.
  • the volume of the solution is preferably 5 ml.
  • This solution is also mixed with the nano delivery component waited in the water.
  • Aqueous nano delivery component added into the mixture is preferably 20 ml and 0,1% w/v.
  • total solution composed by all components is dialyzed against high volume water in dialysis membrane. Pure water in the external medium is constantly changed during dialysis operation.
  • the operation is conducted at preferably 37 °C and for at least 24 hours.
  • nanoparticulates are obtained.
  • the obtained nanoparticulates’ sizes are preferably 120 nm.
  • Table 1 given below shows usable range and preferred quantities by weight of raw materials of clay additive nanoparticulate embodiment.
  • Any clay mineral having layered structures may be used in the nanoparticulate embodiment being subject-matter of the invention.
  • the absolute condition is that the clay mineral must be bio-compatible and be reducible to nano size.
  • Na-MMT is used as delivery component.
  • Any additive polymers having SA characteristic in wet medium can be used in nanoparticulate embodiment.
  • the additive polymer used here has to have amphiphilic characteristic, of which one end dissolves in water and the other end dissolves in oil and also has bio-compatible characteristic.
  • additive polymer preferably PLGA is used.
  • Use of any drug molecules is possible. Particularly, with nanoparticulate embodiment being subject of the invention, the solubility of drugs in water can be enhanced. Moreover, delivery of drug molecules soluble in water is also possible.
  • Reduction of Na-MMT to nano size by mechanical-physical methods prevents increase in size of nano particulate when it interacts with PLGA during next stages.
  • stronger particle formation is provided thanks to interconnecting of PLGA chains. This case prevents disperse of nano delivery agent and releasing drug in points such as strokes and fine liver veins.
  • PLGA is bio compatible and bio-degradable polymer. It is referred to as“Gold Standard” by FDA: When entering into interaction with Na-MMT, toxicity of nano-particulate is prevented.
  • Nanoparticulates obtained by use of method disclosed under the invention can be structured in sizes allowing intravenous administration in targeted cancer treatment applications. Since no chemicals is used during obtaining nanoparticulate process, a nano-particle not containing surfactant or similar toxic agent can be obtained.
  • the invention provides obtaining a nano-particle wherein any drug can be placed and can offer use in many various treatments with SA drug delivery system.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne un procédé d'obtention de composants nanoparticulaires utilisés dans un système d'administration de médicament SA destiné à être utilisé dans des administrations intraveineuses (iv) et caractérisé par le fait qu'il comprend des étapes de procédure consistant à : réduire un composant d'administration en composant de nano-administration par broyage dans un broyeur à attrition ; maintenir le composant de nano-administration obtenu dans l'eau ; dissoudre un polymère additif et un médicament dans l'acétone et le mélanger avec le composant de nano-administration maintenu dans l'eau ; effectuer une dialyse de la solution comprenant le composant de nano-administration, le polymère additif et le médicament pour former un composant nanoparticulaire dans la membrane de dialyse contre un volume élevé d'eau.
PCT/TR2018/050743 2018-11-29 2018-11-29 Procédé d'obtention d'un nanoparticulaire à additif d'argile WO2020112038A1 (fr)

Priority Applications (2)

Application Number Priority Date Filing Date Title
KR1020217007844A KR20210090606A (ko) 2018-11-29 2018-11-29 점토 첨가제 나노미립자를 얻는 방법
PCT/TR2018/050743 WO2020112038A1 (fr) 2018-11-29 2018-11-29 Procédé d'obtention d'un nanoparticulaire à additif d'argile

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/TR2018/050743 WO2020112038A1 (fr) 2018-11-29 2018-11-29 Procédé d'obtention d'un nanoparticulaire à additif d'argile

Publications (1)

Publication Number Publication Date
WO2020112038A1 true WO2020112038A1 (fr) 2020-06-04

Family

ID=70851961

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/TR2018/050743 WO2020112038A1 (fr) 2018-11-29 2018-11-29 Procédé d'obtention d'un nanoparticulaire à additif d'argile

Country Status (2)

Country Link
KR (1) KR20210090606A (fr)
WO (1) WO2020112038A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0600528A1 (fr) * 1992-11-25 1994-06-08 NanoSystems L.L.C. Méthode de brayage de substances pharmaceutiques
WO2012075087A2 (fr) * 2010-11-30 2012-06-07 Board Of Trustees Of The University Of Illinois Conjugués de nanoparticule de silice-agent
CN105617394A (zh) * 2016-01-26 2016-06-01 北京大学 不饱和脂肪酸-抗肿瘤药物偶联物自组装纳米系统及其制备方法和应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0600528A1 (fr) * 1992-11-25 1994-06-08 NanoSystems L.L.C. Méthode de brayage de substances pharmaceutiques
WO2012075087A2 (fr) * 2010-11-30 2012-06-07 Board Of Trustees Of The University Of Illinois Conjugués de nanoparticule de silice-agent
CN105617394A (zh) * 2016-01-26 2016-06-01 北京大学 不饱和脂肪酸-抗肿瘤药物偶联物自组装纳米系统及其制备方法和应用

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"Encapsulation of Hydrophilic and Lipophilic Drugs in PLGA Nanoparticles by the Nanoprecipitation Method", JOSE MARIO BARICHELLO, MARIKO MORISHITA, KOZO TAKAYAMA, AND TSUNEJI NAGAI, DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, vol. 25, no. 4, 1999, pages 471 - 476, XP55714521 *
D. KARATAG ET AL.: "Interaction of curcumin in a drug delivery system including a composite with poly(lactic-co- glycolic acid) and montmorillonite: a density functional theory and molecular dynamics study", JOURNAL OF MATERIALS CHEMISTRY B, 8 May 2017 (2017-05-08), pages 070 - 8082, XP55714522 *

Also Published As

Publication number Publication date
KR20210090606A (ko) 2021-07-20

Similar Documents

Publication Publication Date Title
Wais et al. Nanoformulation and encapsulation approaches for poorly water-soluble drug nanoparticles
He et al. Charge reversal induced colloidal hydrogel acts as a multi-stimuli responsive drug delivery platform for synergistic cancer therapy
JP5405527B2 (ja) 薬理薬物の新規製剤、その製造法及びその使用法
JP2001501931A (ja) 蛋白質安定化した薬理学的活性薬剤、その製造方法およびその使用方法
Guo et al. Direct site-specific treatment of skin cancer using doxorubicin-loaded nanofibrous membranes
CN102327230B (zh) 一种包裹紫杉烷类药物的蛋白纳米颗粒及其制备方法
Li et al. Reduction breakable cholesteryl pullulan nanoparticles for targeted hepatocellular carcinoma chemotherapy
WO2021142884A1 (fr) Utilisation d'aspirine dans la préparation d'un système d'administration de médicament ciblant les plaquettes
CN109771391A (zh) 血小板膜包被的阿霉素-吲哚菁绿仿生纳米颗粒及其用途
CN111617246B (zh) 一种纯光敏剂自组装纳米粒及其制备和应用
Grazia Cascone et al. Poly (vinyl alcohol) hydrogels as hydrophilic matrices for the release of lipophilic drugs loaded in PLGA nanoparticles
JP4991563B2 (ja) 胆汁酸−キトサン複合体内部に疎水性抗癌剤が封入された剤形及びその製造方法
Mohammadi et al. Hybrid in situ-forming injectable hydrogels for local cancer therapy
WO2019007019A1 (fr) Préparation de nanoparticules polymères de psoralène et procédé de préparation associé
CN100493614C (zh) 形成自聚集体的抗癌药-脱乙酰壳多糖复合体以及其制备方法
WO2021042777A1 (fr) Composition pharmaceutique de gel à libération prolongée à composants multiples pour le traitement de tumeurs
CN112826939A (zh) 一种腹腔灌注纳米药物及其制备方法与应用
Khafoor et al. Recent progress in synthesis of nano based liposomal drug delivery systems: A glance to their medicinal applications
Gârea et al. Clay–polymer nanocomposites for controlled drug release
Li et al. Size-transformable nanoparticles with sequentially triggered drug release and enhanced penetration for anticancer therapy
Yang et al. An in situ spontaneously forming micelle-hydrogel system with programmable release for the sequential therapy of anaplastic thyroid cancer
WO2020112038A1 (fr) Procédé d'obtention d'un nanoparticulaire à additif d'argile
CN102357076B (zh) 一种包裹难溶性药物的蛋白纳米颗粒的制备方法
CN1470289A (zh) 一种高分子纳米药物载体和制剂的制备方法
WO2022256417A1 (fr) Système d'administration thérapeutique localisée à base de microparticules à deux étages amélioré

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18941375

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18941375

Country of ref document: EP

Kind code of ref document: A1